Evaluation of renal masses detected by excretory urography: cost-effectiveness of sonography versus CT.
OBJECTIVE
The purpose of this study was to compare the cost-effectiveness of sonography and CT for the evaluation of renal masses discovered at excretory urography.


METHODS
The records of 225 patients with a renal mass shown by urography who then had either sonography or CT within 3 months were reviewed retrospectively. The number, location, and size of lesions; initial and subsequent imaging tests; and final diagnoses were determined. Using the current Medicare reimbursements for sonography and CT, we calculated the economic implications of using sonography or CT as the initial examination. Any effect of the location or size of the lesion on the most cost-effective examination was also determined.


RESULTS
Twenty-one percent of patients had both initial sonography and follow-up CT because of indeterminate findings or detection of a solid mass that required further staging. When CT was done first, CT findings were equivocal in 12%, necessitating follow-up sonography. At the prevailing charges, CT would have to be needed in 70% of patients initially imaged with sonography to justify the use of CT as the initial examination. The location and size of the lesion did not affect the need for CT at a rate (greater than 70%) that would economically justify use of CT as the first imaging test. Eighty-six percent of patients with a mass detected by urography had either a simple cyst or no evidence of a mass on sonography or CT.


CONCLUSIONS
Sonography is the most cost-effective imaging method for the workup of a renal mass detected at urography. The number of sonographic examinations in which findings are indeterminate or positive (for a solid mass) is not sufficiently high to warrant replacement of sonography by CT, regardless of the size and location of the lesion. CT should be reserved for a limited number of specific indications.
Einstein
D M
DM
Division of Radiology, Cleveland Clinic Foundation, OH 44195.
Herts
B R
BR
Weaver
R
R
Obuchowski
N
N
Zepp
R
R
Singer
A
A
D000368:Aged; D003362:Cost-Benefit Analysis; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D052177:Kidney Diseases, Cystic / Q000000981:diagnostic imaging* / Q000191:economics; D007680:Kidney Neoplasms / Q000000981:diagnostic imaging* / Q000191:economics; D008297:Male; D006278:Medicare / Q000191:economics; D012189:Retrospective Studies; D014057:Tomography, X-Ray Computed / Q000191:economics*; D014463:Ultrasonography / Q000191:economics; D014481:United States; D014567:Urography